Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2017 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease

-- PDUFA Action Date Set for August 24, 2017 -- -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson’s Disease -- EMERYVILLE, Calif.,...